NGNE NASDAQ
Neurogene Inc.
1W: -9.4%
1M: +3.7%
3M: +22.8%
YTD: +64.8%
1Y: +46.2%
3Y: +139.0%
5Y: -81.2%
$33.22
-1.40 (-4.04%)
Weekly Expected Move ±12.9%
$26
$30
$35
$39
$44
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$525.0M
52W Range15.93-43.66
Volume135,553
Avg Volume209,730
Beta1.96
Dividend—
Analyst Ratings
Company Info
CEORachel L. McMinn
Employees131
SectorHealthcare
IndustryBiotechnology
IPO Date2014-03-07
Websiteneurogene.com
535 W 24th Street
New York City, NY 10011
US
New York City, NY 10011
US
(877) 237-5020
About Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Latest News
Neurogene Inc. (NASDAQ:NGNE) Receives $84.83 Consensus PT from Analysts
Neurogene (NASDAQ:NGNE) Shares Up 0.1% – Here’s What Happened
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00
Equities Analysts Set Expectations for Neurogene Q1 Earnings
HC Wainwright Weighs in on Neurogene FY2027 Earnings
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cvijic Christine Mik | S-Sale | 4,200 | $36.13 | 2026-07-07 |
| Cvijic Christine Mik | S-Sale | 600 | $36.02 | 2026-07-06 |
| Cvijic Christine Mik | S-Sale | 2,531 | $34.58 | 2026-07-02 |
| Cvijic Christine Mik | S-Sale | 1,530 | $35.23 | 2026-07-02 |
| Cvijic Christine Mik | S-Sale | 739 | $34.06 | 2026-07-01 |